Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current study was undertaken to assess baseline and on-treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J, Sharfman, William H, Kudchadkar, Ragini R, Brohl, Andrew S, Friedlander, Philip A, Daud, Adil, Kluger, Harriet M, Reddy, Sunil A, Boulmay, Brian C, Riker, Adam, Burgess, Melissa A, Hanks, Brent A, Olencki, Thomas, Kendra, Kari, Church, Candice, Akaike, Tomoko, Ramchurren, Nirasha, Shinohara, Michi M, Salim, Bob, Taube, Janis M, Jensen, Erin, Kalabis, Mizuho, Fling, Steven P, Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A, Topalian, Suzanne L
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2021
Schlagworte:
Clinical/Translational Cancer Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8061836/
https://ncbi.nlm.nih.gov/pubmed/33879601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002478
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge